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Primary afferent nociceptorsIn recent years, evidence that sensitization of primary afferent nociceptors is an important event associated
with chronic pain has been accumulating. The present study aimed to evaluate the participation of the pros-
taglandin and sympathetic components in the long-lasting sensitization of nociceptors induced by acute in-
ﬂammation in mice. The intraplantar administration of carrageenan (100 μg) enhanced the nociceptive
response to a small dose of PGE2 (9 ng/paw) or dopamine (3 μg/paw) up to 30 days later. This long-lasting
sensitization is dependent on dopaminergic and prostanoid systems, since the pre-treatment with chlor-
promazine (3 μg/paw) or indomethacin (100 μg/paw), but not local (6 μg/paw) or systemic (6 mg/kg) treat-
ment with morphine, prevented its development. In agreement with this idea, the previous intraplantar
administration of hyperalgesic doses of PGE2 or dopamine also induced long-lasting sensitization, which
was fully prevented by pretreatment with EP4 and D1 antagonists, respectively. In summary, the present
work described in mice a long-lasting sensitization of nociceptors, initiated by an acute inﬂammatory stim-
ulation and dependent on dopaminergic and prostanoid systems. The present data represent new insights
on the mechanisms of peripheral sensitization that could contribute to establish the basis of new therapeutic
strategies for acute and chronic inﬂammatory pain.
© 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
While the physiological pain has an important protective function,
chronic pain can take on a disease character in pathological states, such
as inﬂammation and neuropathy (Kuner, 2010). When pain persists for
years, its broader effects on psychological health and performance of so-
cial responsibilities in work and family life can be profound (Turk and
Rudy, 1988). Chronic pain not only differs from acute pain in its onset
and duration, but also in its underlyingmechanisms, and thus it often re-
sponds poorly to conventional analgesics. Better treatment of chronic
pain will require clear understanding of the mechanisms that contribute
to the transition from an acute tissue insult to chronic pain, and testing of
pharmacological agents in such settings.
Recently, it has been proposed that chronic pain can result from a
persistent sensitization of primary afferent nociceptors, which typicallyahia, Faculdade de Farmácia,
0-290. Tel.: +55 71 32836925;
unb.br (M.I. Funez),
.br (C.A. Parada),
vier OA license. develops as a consequence of tissue insult (Ferreira et al., 1990; Gold
and Gebhart, 2010). The clinical consequence of the sensitization of
nociceptors is allodynia and hyperalgesia, which may correspond to a
reduction in the nociceptive threshold and to an increase in the magni-
tude of the response to noxious stimulation, respectively (Bessou and
Perl, 1969). Although the mechanisms that lead the acute injury to
turn into chronic pain are poorly understood, clinical evidence suggests
a relationship between the sensitization of nociceptors and painmainte-
nance (Gold and Gebhart, 2010). Usually, acute insults resolve without
persisting pain, suggesting that brief nociceptor sensitizations are gener-
ally reversible. On the other hand, during chronic pain states initiated
with tissue lesion, the sensitization tends to be irreversible. In addition,
there are chronic pain states in which tissue pathology is not obvious,
but the peripheral input and nociceptor sensitization are sufﬁcient for
the maintenance of pain (Gracely et al., 1992; Price et al., 2006, 2009;
Staud et al., 2009; Verne et al., 2003). Considering this point of view,
the duration of acute sensitization of nociceptors can be an important
determinant to the development of chronic pain.
In fact, in some clinical chronic pain states, following the resolu-
tion of an episode of acute inﬂammation, an increased susceptibility
to pain induced by subsequent stimuli is observed (Jacobson et al.,
1989; MacIntyre et al., 1995; Melhorn, 1998). In line with this clinical
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produced by carrageenan administration in the rat hind paw, induces
an increased susceptibility to the hyperalgesia mediated by inﬂam-
matory mediators, such as prostaglandins (Aley et al., 2000). Indeed,
prostaglandins are important inﬂammatorymediators that contribute
to the sensitization of nociceptors (Ferreira, 1972; Ferreira and
Nakamura, 1979). In addition to prostaglandins, the involvement of
a sympathetic component has been described (Coderre et al., 1984;
Cunha et al., 2005; Khasar et al., 1999; Nakamura and Ferreira,
1987; Saﬁeh-Garabedian et al., 2002).
The present work aimed to evaluate the participation of prostaglan-
din and sympathetic components in the long-lasting sensitization of
nociceptors induced by local inﬂammation in mice, by using the
hyperalgesic priming model. This study intended to understand mecha-
nisms of nociceptor sensitization and to identify new molecular targets
for pharmacological intervention.
2. Methods
2.1. Animals
Experiments were performed using male Swiss Webster mice
(20–25 g, University of São Paulo, Ribeirão Preto, Brazil). Animals were
housed at 24±1 °C, under a 12:12 h light–dark cycle (lights on at
07:00 AM), with free access to chow and tap water until the day of the
experiment, when only water was made available to them. Animal
care andhandling procedureswere in accordancewith the International
Association for the Study of Pain guidelines for the use of animals in pain
research (Zimmermann, 1983) and the Institutional Animal Care and
Use Committee. All efforts were made to minimize the number of ani-
mals used and any discomfort. Each animal was used only once and all
behavioral testing was performed between 8:00 a.m. and 4:00 p.m. Be-
havioral tests were done without knowing which experimental group
each mouse belonged to.
2.2. Nociceptive mechanical test
Mechanical hyperalgesiawas evaluated inmice using aDynamic Plan-
tar Aesthesiometer (Ugo Basile) test. This apparatus has a pressure trans-
ducer coupled to a digital force detector that records the applied force in
grams. Mice were placed in acrylic cages withwire grid ﬂoors 15–30 min
before starting the test to environment adaptation. The test consists of
evoking a hind paw ﬂexion reﬂex using a ﬁlament-containing Universal
Tip (10 μL, T-300, Axygen) that touches the plantar surface and exerts
an upward force (maximal 50 g) on the plantar surface of the mouse
hind paw. The end point was deﬁned by the withdrawal of the paw
followed by clear ﬂinching movements. With paw withdrawal, the
recorded force was automatically displayed. The results are expressed
by the intensity of hyperalgesia (in grams) calculated by subtracting the
forcemeasured after the treatment from thebasal value (Δ force). The no-
ciceptive threshold ofmousepawsmeasured at theﬁrst experimental day
and before any experimental procedure was considered the baseline
value and was used throughout the experimental period.
2.3. Drug preparation and administration
The agents used in this study were: indomethacin (Prodome,
Campinas, SP, Brazil); morphine sulfate (Cristalia, Itapira, SP, Brazil);
dopamine, chlorpromazine, L741626 (D2 antagonist), SCH-23390
(D1 antagonist), L-745870 (D4 antagonist), AH23848 (EP4 antagonist)
and PGE2 (Sigma, St. Louis, MO, USA); carrageenan (FMC, Philadel-
phia, USA). All the drugs were dissolved in 0.15 M NaCl (saline), ex-
cept for indomethacin, which was dissolved in Tris buffer (Merck,
Darmstadt, Germany) and for PGE2, which was stored in dimethyl
sulfoxide 2% (Sigma, St. Louis, MO, USA) and dissolved in saline. All
drugs were administrated locally (hind paw, intraplantar — i.pl.)with a 29 G hypodermic needle in a volume of 25 μL per paw, with
the exception of morphine, which was also delivered systemically
by subcutaneous (s.c.) route.
2.4. Statistical analysis
Results are presented as means±SEM of measurements made on
6 animals in each group and represent the intensity of hyperalgesia.
The curves were analyzed by two-way ANOVA to ﬁnd interactions be-
tween time and treatment. To analyze distinct points of the curves we
used one-way ANOVA followed by Bonferroni's pos-test. Differences
were considered to be statistically signiﬁcant at pb0.05.
2.5. Experimental protocols
Induction of long-lasting sensitization of nociceptors: in this protocol
the effects of a single administration of a pro-inﬂammatory agent (carra-
geenan) or two agents known to be released by carrageenan (PGE2 and
dopamine; Nakamura and Ferreira, 1987) were evaluated. In the ﬁrst ex-
perimental day, the nociceptive thresholdwas evaluated before any treat-
ment. Carrageenan (100 μg), PGE2 (90 ng), dopamine (30 μg), or saline
were administeredby intraplantar route, and the intensity of hyperalgesia
was evaluated 2–3 h later. Aiming to quantify the long-lasting sensitiza-
tion, the response to an intraplantar injection of PGE2 (9 ng or 90 ng), do-
pamine (3 μg) or saline was evaluated 5 or 30 days after the acute
inﬂammation. The intensity of hyperalgesia was evaluated at different
times, as indicated in the ﬁgures.
We also tested the effects of pre-treatment with the cyclooxygenase
inhibitor indomethacin, the dopamine-receptor antagonist chlorproma-
zine, and themorphine against carrageenan-induced sensitization. Indo-
methacin (100 μg/paw), chlorpromazine (100 μg/paw), and morphine
(6 μg/paw) were administered 30 min before the carrageenan injection
at doses derived from previous studies (Cunha et al., 2005). Morphine
(6 mg/kg) was also administered by subcutaneous route 30 min before
and 12 h after the carrageenan administration. In addition, the effects
of dopamine antagonists (D2, L741626; D1, SCH23390; D4, L745870)
and PGE2 antagonist (EP4, AH23848) were evaluated in PGE2- or
DA-induced sensitization.
3. Results
In the present study, we describe a long-lasting sensitization of
nociceptors induced by local inﬂammation in mice, which is depen-
dent on the dopaminergic and prostanoid systems. As shown in
Fig. 1, the intraplantar treatment with carrageenan (100 μg) in the
ﬁrst experimental day produced a short-term hyperalgesia from
which the animals fully recovered, with values similar to normal
baseline at experimental days ﬁve (Fig. 1a) and thirty (Fig. 1b). Sub-
cutaneous intraplantar injection of a small dose of PGE2 (9 ng/paw)
or dopamine (3 μg/paw), at the same site into which carrageenan
had been injected 5 or 30 days earlier, resulted in an increased
hyperalgesic response. During this sensitized state, the mechanical no-
ciceptive threshold has returned to pre-carrageenan values (Fig. 1, day 5
and day 30). However, administration of PGE2 or dopamine, at doses
that only induce a slight and brief hyperalgesia in normal conditions, in-
duced an improved hyperalgesic effect (Fig. 1).
Because the carrageenan-induced hyperalgesia inmice is dependent
on prostaglandins and sympathetic amines, the contribution of these
two components to inﬂammation-induced long-lasting sensitization
was evaluated. The pre-treatment with a cyclooxygenase inhibitor,
indomethacin (100 μg/paw), or a dopaminergic antagonist, chlorprom-
azine (3 μg/paw), partially inhibited the carrageenan-induced acute
hyperalgesia, but completely prevented the development of the long-
lasting sensitization (Fig. 2a). On the other hand, the systemic
pre-treatment with morphine (6 mg/kg/s.c.; Fig. 2b) twice in the ﬁrst
experimental day, fully prevented the acute hyperalgesia induced by
Fig 1. Increased response to hyperalgesic mediators induced by previous local inﬂam-
mation. Panels a and b represent acute hyperalgesia induced by i.pl. injection of carra-
geenan (Cg; 100 μg) in the ﬁrst experimental day (day 1) and hyperalgesic response
induced by i.pl. injection of a small dose of PGE2 (9 ng) or dopamine (DA; 3 μg)
5 days (day 5; panel a) or 30 days (day 30; panel b) latter. Full and open arrows rep-
resent the moment of carrageenan and PGE2 or dopamine administration, respectively.
The nociceptivemechanical thresholdwas evaluated before and 3 h after drug administra-
tion. Data are reported as means±SEM; n=6mice per group. (*pb0.001 vs. saline/saline
group. #pb0.001 vs. saline/DA group. $pb0.001 vs. saline/PGE2 group; repeated measures
of two-way ANOVA followed by the Bonferroni's test).
Fig. 2. Effects of pre-treatment with indomethacin, chlorpromazine and morphine in the
increased response to hyperalgesic mediators induced by previous inﬂammation. Panel a
represents acute hyperalgesia induced by i.pl. injection of carrageenan (Cg; 100 μg) in
the ﬁrst experimental day (day 1) and hyperalgesic response induced by a small dose of
PGE2 (9 ng/paw) 5 days after (day 5). Previously to carrageenan administration (30 min
before), the animals received saline, indomethacin (In; 100 μg/paw), chlorpromazine
(CLP; 3 μg/paw) or indomethacin+chlorpromazine (CLP+In; at the same doses). Five
days later the hyperalgesic response to PGE2 (9 ng/paw) was evaluated. Full and open ar-
rows represent themoment of carrageenan and PGE2 administration, respectively. Panel b
shows the hyperalgesic response to PGE2 (9 ng/paw) in mice pre-treated with morphine
and carrageenan 5 days before. Previously to carrageenan administration (30 min before),
the animals received an intraplantar injection ofmorphine (Mo i.pl.; 6 μg/paw). In another
experimental group,morphine (Mo; 6 mg/kg)was administrated systemically by subcuta-
neous route twice 24 h before carrageenan. The nociceptive mechanical threshold was
evaluated before and 3 h after drug administration. Data are reported as means±SEM;
n=6 mice per group. (*pb0.01 vs. saline/saline/PGE2 group; #pb0.001 vs. remaining
groups; repeated measures of two-way ANOVA followed by the Bonferroni's test).
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sensitization. Similar proﬁle of activity was observed with the
intraplantar injection of morphine (6 μg/paw). Intraplantar injection
of a small dose of PGE2 (9 ng/paw) or dopamine (3 μg/paw), at the
same site where PGE2 (90 ng/paw; Fig. 3a) or dopamine (30 μg/paw;
Fig. 3b) had been injected 5 days earlier, also resulted in an increased
hyperalgesic response.
To determine the pharmacological receptors involved with the
long-lasting sensitization of nociceptors in mice, the effects of the
pre-treatment with PGE2 or dopamine antagonists were evaluated.
The pre-treatment with a D1 antagonist (SCH23390, 27–240 μg/paw;
Fig. 4b), but not with D2 and D4 antagonists (L741626, 11–100 μg/paw
and L745870, 11–100 μg/paw; Fig. 4a and c, respectively) fully
prevented the acute hyperalgesia induced by dopamine and the
induction of the long-lasting sensitization. Similarly, the pre-treatment
with an EP4 antagonist (AH23848, 10–1000 ng/paw; Fig. 5), fully
prevented the acute hyperalgesia and the long-lasting sensitization in-
duced by PGE2. The pre-treatment with a D1 antagonist (SCH23390,
240 μg/paw) did not prevent the long-lasting sensitization induced by
PGE2. Similarly, the pre-treatment with the EP4 antagonist (AH23848,
1000 ng/paw) did not prevent the sensitization induced by dopamine
(data not shown).
4. Discussion and conclusions
Over the past 20 years, the most successful analgesic development
activities have been conﬁned to reformulation of conventional anal-
gesic drugs, such as opioids and AINEs (Kissin, 2010). Consideringthat the majority of the existing analgesics for chronic pain are rela-
tively ineffective and do not reduce pain in all treated individuals,
new strategies are needed. In this context, the elucidation of mecha-
nisms that underlie the transition from acute inﬂammatory pain sen-
sation to chronic pain is crucial to deﬁne new pharmacological
approaches. The aim of the present study was to verify whether pros-
taglandins and sympathomimetic amines released during inﬂamma-
tion of peripheral tissue could increase the susceptibility of primary
sensorial neurons to subsequent sensitizations. In fact, Aley et al.
(2000) demonstrated that acute paw inﬂammation chronically in-
creases the susceptibility of primary sensorial neurons to the inﬂam-
matory mediators induced hyperalgesia. Such an increased of the
susceptibility of the primary afferent neurons could underlie the de-
velopment of chronic pain. In the present study we describe, in a
mouse model, a long-lasting sensitization of nociceptors induced by
local inﬂammation that can represent the priming state previously
described in rats (Aley et al., 2000). As shown here, a single episode
of acute inﬂammation created a state of increased susceptibility to
hyperalgesic mediators, such as PGE2 and dopamine. Therefore, levels
of inﬂammatory mediators that would be painless in the normal ani-
mal may cause signiﬁcant pain in the sensitized state.
Fig. 3. Increased response to hyperalgesic mediators induced by PGE2 and dopamine.
Panels represent acute hyperalgesia induced by i.pl. administration of PGE2 (panel a;
90 ng/paw) or dopamine (panel b; 30 μg/paw) in the ﬁrst day (day 1) of the experi-
mental period. Five days latter (day 5), the hyperalgesic response of this mice to a
small dose of PGE2 (9 ng/paw), or dopamine (3 μg/paw) was evaluated. The nocicep-
tive mechanical threshold was measured before and after drug administration at the
times indicated in the ﬁgure. Arrows represent the moment of intraplantar injections.
Data are reported as means±SEM; n=6 mice per group. (*pb0.001 vs. saline/saline
group. #pb0.001 vs. saline/DA group. $pb0.001 vs. saline/PGE2 group; repeated mea-
sures of two-way ANOVA followed by the Bonferroni's test).
Fig. 4. Effects of pre-treatment with dopaminergic antagonists in the increased re-
sponse to hyperalgesic mediators induced by dopamine. Figure represents acute
hyperalgesia induced by i.pl. injection of dopamine (DA; 30 μg/paw) in the ﬁrst exper-
imental day (day 1, full arrow) and hyperalgesic response induced by a small dose of
DA (3 μg/paw) 5 days after (day 5, open arrow). Previously to dopamine administra-
tion (30 min before), the animals received saline (25 μL/paw), D2 antagonist
(L741626; panel a), D1 antagonist (SCH-23390; panel b), or D4 antagonist (L745870;
panel c). The nociceptive mechanical threshold was evaluated before and 3 h after
drug administration. Data are reported as means±SEM; n=6 mice per group.
(*pb0.001 vs. saline/saline group; #pb0.001 vs. saline/DA group; repeated measures
of two-way ANOVA followed by the Bonferroni's test).
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associated changes in the chemical environment of the primary affer-
ent ﬁbers (McMahon et al., 2008). After the inﬂammatory stimuli, a
wide array of endogenous factors, such as neurotransmitters, eicosa-
noids, and cytokines are released from activated nociceptors or
non-neural cells. The interactions between cell-surface receptors of
nociceptors and these factors enhance excitability of nociceptors,
thereby raising its sensitivity to subsequent stimulus (Basbaum et
al., 2009). These events can induce a temporary sensitization of the
affected area or a persistent sensitization associated with unremitting
pain. Carrageenan, which was used to induce the initial inﬂammation
in the present work, is a classical agent for the induction of experi-
mental inﬂammation, a model considered relevant due to its similar-
ity to clinically important inﬂammatory pain states (Dawson et al.,
1991; Di Rosa, 1972). The carrageenan-induced hyperalgesia in mice
is dependent on prostaglandins and sympathetic amines (Cunha et
al., 2005; Nakamura and Ferreira, 1987). These two mediators are in-
volved in sensitization of nociceptors (Cunha et al., 2005; Ferreira and
Nakamura, 1979; Khasar et al., 1999; Nakamura and Ferreira, 1987).
Prostaglandins and sympathetic amines are present at sites of
inﬂammation (Bley et al., 1998; Villena et al., 1999) and produce
hyperalgesia by a direct action on primary afferent nociceptors (Ferreira
et al., 1978; Gold et al., 1996). Sympathetic amines (norepinephrine and
dopamine) have also been shown to functionally up-regulate nociceptors
(Coderre et al., 1984; Duarte et al., 1988; Nakamura and Ferreira, 1987;
Wall and Gutnick, 1974). In the present study, the pre-treatmentwith in-
domethacin or chlorpromazine completely prevented the developmentof the long-lasting sensitization, suggesting that this phenomenon is de-
pendent on the activation of dopaminergic and prostanoid systems.
Corroborating with this idea, the preceding intraplantar administration
of PGE2 or dopamine, at hyperalgesic doses, also prolonged and enhanced
the nociceptive response to subsequent administration of hyperalgesic
mediators. These results suggest that similar messenger systemsmediate
both acute hyperalgesia and long-lasting peripheral sensitization during
inﬂammatory conditions. To evaluate whether the induction of the
nociceptor sensitization requires a hyperalgesic event, mice were
pretreated with an analgesic dose of morphine. Morphine fully
prevented the acute hyperalgesia, but did not affect the long-lasting
Fig. 5. Effects of pre-treatment with EP4 receptor antagonist in the increased response to
hyperalgesic mediators induced by PGE2. Figure represents acute hyperalgesia induced by
i.pl. injection of PGE2 (90 ng/paw) in the ﬁrst experimental day (day 1) and hyperalgesic
response induced by a small dose of PGE2 (9 ng/paw) 5 days after (day 5). Previously to
PGE2 administration (30 min before), the animals received saline (25 μL/paw)or EP4 antag-
onist (AH23848). Arrows represent the moment of the intraplantar injections of PGE2. The
nociceptive mechanical threshold was evaluated before and 3 h after drug administration.
Data are reported as means±SEM; n=6 mice per group. (*pb0.001 vs. saline/saline
group; #pb0.001 vs. remaining groups; repeated measures of two-way ANOVA followed
by the Bonferroni's test).
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of nociceptor sensitization is not dependent on the nociceptive experi-
ence per se, but rather to an activation of speciﬁc receptors and intracel-
lular signaling pathways.
Next, the pharmacological receptors involved with the sensitiza-
tion of nociceptors were evaluated. The pharmacological antagonism
of D1 and EP4 receptors fully prevented the acute hyperalgesia and
the long-lasting sensitization induced by dopamine and PGE2, respec-
tively. In line with the present results observed in mice, a key role of
D1 receptor subtype in the hyperalgesia induced by intraplantar injec-
tion of dopamine was previously demonstrated in rats (Ferreira et al.,
1990). Similarly, the EP4 receptors expressed on primary afferent sen-
sory neurons have been associated with PGE2-mediated sensitization
and hyperalgesia in models of acute and chronic inﬂammatory pain
(Lin et al., 2006; Nakao et al., 2007). D1 and EP4 receptors stimulate
the adenylyl cyclase/adenosine 30,50-cyclic monophosphate (cAMP)
secondary messenger pathway (Coleman et al., 1994; Memo et al.,
1986; Missale et al., 1998; Monsma et al., 1990; Sugimoto and
Narumiya, 2007), which plays a pivotal role in the sensitization of
nociceptors during inﬂammation (Cunha et al., 1999; Ferreira and
Nakamura, 1979; Ouseph et al., 1995; Taiwo et al., 1989; Taiwo and
Levine, 1991; Villarreal et al., 2009). This data suggest that the
long-lasting sensitization induced by PGE2 or dopamine may involve
enhancement of intracellular cAMP.
In summary, the present work described in mice a long-lasting sen-
sitization of nociceptors, initiated by an acute inﬂammatory stimulation
which is dependent on the activation of dopaminergic and prostanoid
systems. This long-lasting pronociceptive state or nociceptive memory
may be considerate a phenomenon of primary afferent nociceptors plas-
ticity, and is probably present in chronic inﬂammatory pain. The concept
of peripheral nociceptive memory will allow us to better understand
chronic pain and its therapeutics. The present data bring new insights
into mechanisms of peripheral sensitization that could contribute to
form the basis of new therapeutic strategies for treating acute and
chronic inﬂammatory pain.Acknowledgments
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